The poor outcome of pancreatic cancer with conventional treatment options emphasizes the need for continued research. The benefits of gemcitabine in improving quality of life and survival have been established in patients with advanced pancreatic cancer. Randomized clinical trials studying the addition of a second drug to gemcitabine, either a classic cytotoxic (5-fluorouracil, cisplatin, irinotecan, pemetrexed, oxaliplatin, or exatecan) or targeted agents (ie, the farnesyl transferase inhibitor R115777 or the metalloproteinase inhibitor marimastat) have not resulted in improvement in survival compared with gemcitabine alone. Although limited activity of docetaxel in patients with pancreatic adenocarcinoma has been reported in single-agent studies, attractive efficacy results have been documented with docetaxel in combination with other chemotherapeutic agents for the management of advanced pancreatic cancer. Phase I and II trials of docetaxel in combination with gemcitabine, irinotecan, 5-fluorouracil, or thalidomide, as well as trials of docetaxel and radiotherapy, suggest that docetaxel combinations in pancreatic cancer should be further studied in randomized trials.

中文翻译：

---

多西紫杉醇在晚期胰腺癌的管理中。

采用常规治疗方案的胰腺癌预后较差，这表明需要继续进行研究。在晚期胰腺癌患者中，吉西他滨改善生活质量和生存的益处已得到证实。研究在吉西他滨中添加第二种药物（一种经典的细胞毒性药物（5-氟尿嘧啶，顺铂，伊立替康，培美曲塞，奥沙利铂或Exatecan））或靶向药物（即，法呢基转移酶抑制剂R115777或金属蛋白酶抑制剂marimastat）的随机临床试验与单独使用吉西他滨相比，尚无改善生存率的方法。尽管单药研究表明多西紫杉醇对胰腺腺癌患者的活性有限，多西紫杉醇与其他化疗药物联合用于晚期胰腺癌的治疗已证明具有诱人的疗效。多西紫杉醇联合吉西他滨，伊立替康，5-氟尿嘧啶或沙利度胺的I和II期临床试验以及多西紫杉醇和放疗的试验表明，多西紫杉醇组合治疗胰腺癌应在随机试验中进一步研究。